Trade Lantheus Holdings Inc - LNTH CFD

Lantheus Holdings Inc Company profile

About Lantheus Holdings Inc

Lantheus Holdings, Inc. is a provider of imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to Find, Fight and Follow serious medical conditions. It operates through two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its agents and products throughout the United States. The International Segment operations consist of direct distribution in Canada and Puerto Rico, as well as third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific and Latin America and its EXINI business in Sweden. The Company sells its products to radio pharmacies, PET manufacturing facilities (PMFs), integrated delivery networks, hospitals, clinics and group practices. Its commercial portfolio includes DEFINITY, TechneLite, NEUROLITE, RELISTOR, Xenon-133, Cardiolite, Gallium-67, Thallium-201, AZEDRA, QUADRAMET, Cobalt and Automated Bone Scan Index (aBSI).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Lantheus Holdings Inc revenues increased 25% to $425.2M. Net loss increased from $13.5M to $71.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Other General and administrative increase from $50M to $141.3M (expense), Other Sales and marketing expense increase of 69% to $66M (expense).